Universal Display OLED Increase (Decrease) in Contract with Customer, Asset

Increase (Decrease) in Contract with Customer, Asset at other companies

West Pharmaceutical ServicesWST

——

Revenue$142.2M-14.5%

Gross profit$106.1M-17.2%

Operating income$42.8M-38.6%

Net income$35.9M-44.3%

EPS (diluted)$0.76-43.7%

Cash & equivalents$159.4M—

Total debt$40.9M—

Total equity$1.7B+2.7%

Total assets$1.9B—

Operating cash flow$108.9M+256%

CapEx$8.6M-34.1%

Free cash flow$100.3M+473%

Market cap$4B-34.8%

Gross margin75.7%-1.2pp

Operating margin35.4%-2.5pp

Net margin34.1%-1.3pp

FCF margin37.8%+12.6pp

Return on equity12.7%-1.9pp

Debt / equity0×—

Current ratio9.5×—

Reported directly by Universal Display in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerAsset.

The official record: Universal Display’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Universal Display's increase (decrease) in contract with customer, asset?: Universal Display (OLED) reported increase (decrease) in contract with customer, asset of $16.37M in Q1 2026.
How has Universal Display's increase (decrease) in contract with customer, asset changed year-over-year?: Universal Display's increase (decrease) in contract with customer, asset decreased by 47.9% year-over-year, from $31.44M to $16.37M.